Boston Scientific Corp. said Thursday that it launched its Taxus Element drug-coated coronary stent in Europe, and that physicians there have started using the device in surgical procedures.
Stents are mesh-metal devices that are used to prop open arteries after they have been surgically cleared of fatty plaque. Some stents, including Taxus Element, are coated with drugs to prevent scar tissue from blocking the artery.
European Union regulators approved the stent last month, Boston Scientific said, adding that the approval included a specific indication for diabetes patients. The Taxus Element system also includes a catheter delivery system.
Boston Scientific stock rose 7 cents to $5.51 in afternoon trading.